Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …

Background Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
which has shown robust anti-tumour efficacy, along with intracranial activity, in patients with …

Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …

8059 Background: In the ASCEND-1 study ceritinib showed clinical activity in pts with ALK+
NSCLC, including in brain metastases (BM). ASCEND-2 (NCT01685060) evaluated efficacy …

Background Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …

8003^ Background: ALK+ NSCLC is sensitive to crizotinib (CRZ) but patients (pts) invariably
progress. Ceritinib (LDK378) is a novel ALK inhibitor (ALKi) more potent than CRZ in …

Introduction Induction of programmed death ligand 1 (PD-L1) expression due to constitutive
oncogenic signaling has been reported in NSCLC models harboring echinoderm …

Background Currently, crizotinib is the only drug that has been approved for treatment of
ALK-rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and …

8060 Background: Ceritinib demonstrated clinical activity in ALKi-pretreated and-naïve pts
with ALK+ NSCLC, including those with brain metastases (BM; pivotal ASCEND-1 study) …

Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-
rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and …